Back to top
Dr Annunziata (Nancy) Dattola

Dr Annunziata (Nancy) Dattola

Researcher at the Department of Dermatology

Dr Annunziata (Nancy) Dattola is Researcher at the Department of Dermatology, University of La Sapienza in Rome, Italy.

 

Her main field of interest is the diagnosis and treatment of inflammatory skin diseases. In 2013, Dr Dattola completed a 2-year fellowship at the Laboratory for Investigative Dermatology at the Rockefeller University, New York, NY. During her fellowship, she focused on psoriasis, metabolic syndrome and imaging such as positron emission tomography (PET)/computerised tomography (CT), sono-elastography, and CT angiography, in the diagnosis of patients with psoriasis. In January 2021, she completed her PhD in Biochemistry and Molecular Biology with a thesis entitled: “Results of two different biological treatments in patients with PsO and PsA, and detection of early arthritis”.

 

Dr Dattola’s current research includes projects on biological agents for the treatment of psoriasis, laser and cosmetology. She is also involved in numerous phase III clinical trials and is author of many papers on these topics. She completed 3 years of research at the University of Rome Tor Vergata from 2018 to 2021.

 

Dr Dattola is a member of the “Italian task force” for women with psoriasis, member of the Italian Society of Dermatology and Venereology (SIDeMaST), member of the European Academy of Dermatology and Venereology (EADV) and member of the local organising committee for the World Congress of Dermatology 2019 Milan, Italy.

0 resources
Image
Screenshot 2025-05-30 at 13.48.40.png
Video41:11 min
Navigating the new European S2k guidelines for hidradenitis suppurativa: How will they change your clinical practice?

Prof. Tzellos, Dr Martorell, Dr McGrath and Prof. Jemec detail HS treatment options, the role of imaging and the HCP-patient relationship.

EU-BK-2500021
Image
Video 10 LH HS.png
Video6:55 min
Setting up MDT care in HS: Learning from psoriasis

Establishing a multidisciplinary team to alleviate disease burden and optimise patient outcomes, using the principles of value-based healthcare

EU-DA-2400507